Neville Rodie & Shaw Inc Gilead Sciences, Inc. Transaction History

Neville Rodie & Shaw Inc

$1.36 Billion
Q3 2024

A detailed history of Neville Rodie & Shaw Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Neville Rodie & Shaw Inc holds 14,851 shares of GILD stock, worth $1.37 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

14,851

Previous 15,696 5.38%

Holding current value

$1.37 Million

Previous $1.08 Million 15.6%

% of portfolio

0.09%

Previous 0.08%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 01, 2024	SELL	$66.59 - $83.99 $56,268 - $70,971	-845 Reduced 5.38%	14,851 $1.25 Million
Q2 2024 Jul 01, 2024	SELL	$63.15 - $72.88 $18,945 - $21,864	-300 Reduced 1.88%	15,696 $1.08 Million
Q4 2023 Jan 02, 2024	SELL	$73.27 - $83.09 $9,158 - $10,386	-125 Reduced 0.78%	15,996 $1.3 Million
Q2 2023 Jul 06, 2023	SELL	$76.01 - $86.7 $167,222 - $190,740	-2,200 Reduced 12.01%	16,121 $1.24 Million
Q3 2022 Oct 04, 2022	SELL	$59.54 - $68.01 $17,862 - $20,403	-300 Reduced 1.61%	18,321 $1.13 Million
Q2 2022 Jul 06, 2022	BUY	$57.72 - $65.01 $44,271 - $49,862	767 Added 4.3%	18,621 $1.15 Million
Q1 2022 Apr 05, 2022	SELL	$57.92 - $72.58 $23,168 - $29,032	-400 Reduced 2.19%	17,854 $1.07 Million
Q4 2021 Jan 05, 2022	SELL	$64.88 - $73.64 $6,488 - $7,364	-100 Reduced 0.54%	18,254 $1.33 Million
Q2 2021 Jul 06, 2021	SELL	$63.47 - $69.35 $54,584 - $59,640	-860 Reduced 4.48%	18,354 $1.26 Million
Q1 2021 Apr 08, 2021	SELL	$60.0 - $68.46 $174,720 - $199,355	-2,912 Reduced 13.16%	19,214 $1.24 Million
Q4 2020 Mar 04, 2021	SELL	$56.65 - $64.55 $87,920 - $100,181	-1,552 Reduced 6.55%	22,126 $1.29 Million
Q3 2020 Oct 01, 2020	SELL	$62.1 - $78.08 $107,122 - $134,688	-1,725 Reduced 6.79%	23,678 $1.5 Million
Q2 2020 Jul 15, 2020	SELL	$72.34 - $84.0 $179,041 - $207,900	-2,475 Reduced 8.88%	25,403 $1.96 Million
Q1 2020 Apr 01, 2020	SELL	$62.63 - $80.22 $143,861 - $184,265	-2,297 Reduced 7.61%	27,878 $2.08 Million
Q4 2019 Jan 08, 2020	SELL	$61.62 - $67.78 $31,734 - $34,906	-515 Reduced 1.68%	30,175 $1.96 Million
Q3 2019 Oct 02, 2019	SELL	$62.51 - $69.0 $70,323 - $77,625	-1,125 Reduced 3.54%	30,690 $1.95 Million
Q2 2019 Jul 01, 2019	SELL	$61.87 - $69.38 $328,282 - $368,130	-5,306 Reduced 14.29%	31,815 $2.15 Million
Q1 2019 Apr 08, 2019	SELL	$62.53 - $70.05 $183,463 - $205,526	-2,934 Reduced 7.32%	37,121 $2.41 Million
Q4 2018 Jan 03, 2019	SELL	$60.54 - $79.0 $43,528 - $56,801	-719 Reduced 1.76%	40,055 $2.51 Million
Q3 2018 Oct 09, 2018	SELL	$71.28 - $78.92 $19,887 - $22,018	-279 Reduced 0.68%	40,774 $3.15 Million
Q2 2018 Jul 03, 2018	BUY	$64.88 - $75.68 $24,265 - $28,304	374 Added 0.92%	41,053 $2.91 Million
Q1 2018 Apr 12, 2018	SELL	$72.84 - $88.8 $16,971 - $20,690	-233 Reduced 0.57%	40,679 $3.07 Million
Q4 2017 Jan 03, 2018	SELL	$71.15 - $83.52 $4,909 - $5,762	-69 Reduced 0.17%	40,912 $2.93 Million
Q3 2017 Oct 03, 2017	BUY	$72.11 - $85.47 $2.96 Million - $3.5 Million	40,981	40,981 $3.32 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Neville Rodie & Shaw Inc, based on Form 13F filings with the SEC.

News

Stay updated on Neville Rodie & Shaw Inc with notifications on news.

Account

Neville Rodie & Shaw Inc Gilead Sciences, Inc. Transaction History